46
LIPIDS & DYSLIPOPROTEINEMIA Merlyn A. Baraclan, RN, RMT

lipids & dyslipoproteinemia

Embed Size (px)

DESCRIPTION

Clinical Chemistry 1

Citation preview

Page 1: lipids & dyslipoproteinemia

LIPIDS & DYSLIPOPROTEINEMIA

Merlyn A. Baraclan, RN, RMT

Page 2: lipids & dyslipoproteinemia

TOPIC OUTLINE Overview on Lipids Lipoproteins,

Apoliporoteins & Related Proteins

Lipid Transport & Lipoprotein Metabolism

Lipid & Lipoprotein Measurement

The NCEP Guidelines Lipids, Lipoproteins &

Disease References

Page 3: lipids & dyslipoproteinemia

LIPIDS are biological

compounds which are soluble in nonpolar organic solvents but relatively insoluble in polar solvents.

Page 4: lipids & dyslipoproteinemia

MAJOR BODY LIPIDS

Triglycerides / TAG / TG Cholesterol / C Phospholipids

Glycolipids

Page 5: lipids & dyslipoproteinemia

BIOLOGIC ROLES OF LIPIDS

Primary source of fuel Components of cell membranes &

many cell structures Provide stability to cell membranes Means of transmembrane transport

Page 6: lipids & dyslipoproteinemia

LIPOPROTEINS

The function of lipoprotein particle is to transport lipids around the body in the blood.

Contain cholesterol in 2 forms: _ free cholesterol_ cholesterol ester

Lipoproteins have a micellar structure.

Page 7: lipids & dyslipoproteinemia

LIPOPROTEINS The transport proteins of lipids

having a micellar structure composed of two parts as follows:

Central corecontains TAG and cholesterol ester

nonpolar moiety

Surface coatcontains PL, free cholesterol, and apolipoproteins

Page 8: lipids & dyslipoproteinemia

4 MAJOR LIPOPROTEIN CLASSES

- Chylomicrons (CM) - very low density lipoproteins

(VLDL)

- low density lipoproteins (LDL)

- high density lipoproteins (HDL)

Page 9: lipids & dyslipoproteinemia

LIPOPROTEINSCLASS DENSITY

(g/ml)MEAN

DIAMETER

(mm)

source Principal function

Electropho

retic mobility

CM < 0.95 500 intestine Transport ofExogenous

TAG

Remains at Origin

VLDL 0.96 -1.006

43 liver Transport of Endogenous

TAG

Pre β

IDL 1.007-1.019

27 Catabolism of VLDL

Precursor of LDL

“broad β”

LDL 1.020-1.063

22 Catabolism of VLDL via IDL

CholesterolTransport

β

HDL 1.064-1.210

8 Liver,intestine,catabolism of CM & VLDL

“reversecholesteroltransport”

α

Page 10: lipids & dyslipoproteinemia

CHEMICAL COMPOSITION OF MAJOR CLASSES OF PLASMA PROTEINS

CLASS PROTEIN%

TAG%

CHOLESTEROL%

PHOSPHO LIPID

%

Chylomicron/ CM

1-2 85 - 95 3 -5 5 -10

VLDL 10 60 -70 10 -15 10 – 15

LDL 15 -25 5 - 10 45 20 -30

HDL 50 Verylittle

20 30

Page 11: lipids & dyslipoproteinemia
Page 12: lipids & dyslipoproteinemia
Page 13: lipids & dyslipoproteinemia

LIPOPROTEINS , APOLIPOPROTEINS & RELATED PROTEINS

MAJOR LIPOPROTEINS

1. CHYLOMICRONS / CM- Produced by the intestine- Transport lipids of dietary origin- Poor in free cholesterol- Has a “very high lipid/protein ratio- “milky plasma”- “Floating creamy layer”- Removed by the liver

Page 14: lipids & dyslipoproteinemia

MAJOR LIPOPROTEINS

2. VERY LOW DENSITY LIPOPROTEINS / VLDL

- Produced by the liver- Supplies the body w/ TAG of

endogenous origin & also cholesterol- “ turbid plasma”

Page 15: lipids & dyslipoproteinemia

MAJOR LIPOPROTEINS

3. LOW DENSITY LIPOPROTEINS / LDL

- Produced by the metabolism of VLDL- The particles do not scatter light- Removed by the liver & macrophages

Page 16: lipids & dyslipoproteinemia

MAJOR LIPOPROTEINS 4. HIGH DENSITY LIPOPROTEIN /

HDL

- Consists mostly of proteins- Produced by the liver- “reverse cholesterol transport”- Cardioprotective

Page 17: lipids & dyslipoproteinemia

MINOR & ABNORMAL LIPOPROTEINS

1. Lipoprotein (a) / Lp (a)- Similar to LDL - Synthesized in the liver- “lipid staining pre β band”- Has atherogenic properties- 2. LPX Lipoprotein- Seen in patients with obstructive biliary

disease, & with LCAT deficiency- 3. β – VLDL - “Floating β lipoprotein”

Page 18: lipids & dyslipoproteinemia

EXOGENOUS (DIETARY) LIPID PATHWAYFood intestinal absorption

CM High TAG,Low Chol, Apo B48

TAG in adipose tissue

Muscle & FFA

chylomicron remnants taken by the liver

Page 19: lipids & dyslipoproteinemia

ENDOGENOUS LIPID PATHWAY FFA TAG synthesis in liver, intestine VLDL

High TAG

Low Chol

FFA Apo B100

LPL Apo E

IDL

Apo E Binds onto hepatocytes through Apo E

LDL LDL binds to the receptors in liver (70%)

& other tissues (30%)

Page 20: lipids & dyslipoproteinemia

HDL PATHWAYliver secretes Apo A1 + other Apos + PLs Nascent

HDL

Cholesterol from tissues

HDL 3

Esterification of Cholestrol by LCAT

LDL

uptake by liver

Cholesterol transfer to VLDL

excretion into bile

Page 21: lipids & dyslipoproteinemia

C.1 BLOOD SAMPLING & STORAGE

BIOLOGIC VARIATION FASTING POSTURE

VENOUS VS. CAPILLARY

PLASMA VS. SERUM STORAGE

Page 22: lipids & dyslipoproteinemia

BLOOD SAMPLING & STORAGE

BIOLOGIC VARIATION- Cholesterol level rises w/ age - Women have lower levels than

men (except in childhood & after the early 50’s)

- Age related variation is the basis of NCEP recommendation that cholesterol screening be repeated every 5 years.

Page 23: lipids & dyslipoproteinemia

BLOOD SAMPLING & STORAGE FASTING- 12 hours before venipuncture- Chylomicrons are completely cleared

w/in 6 – 9 hours - NCEP Adult Treatment Panel III( ATP III),

has recommended that patients fast for at least 9 hours before blood specimens are taken for lipid & lipoprotein analysis

POSTURE- Current NCEP guidelines recommend

that patients be seated for 5 minutes prior to sampling.

Page 24: lipids & dyslipoproteinemia

BLOOD SAMPLING & STORAGE VENOUS VS. CAPILLARY SAMPLES- Measurements in capillary blood samples

are lower than venous samples & tend to be more variable.

PLASMA VS. SERUM- Either plasma or serum can be used when

only TAG, cholesterol & HDL are measured, & LDL – C is calculated from these three measurements.

- Plasma is preferred when lipoproteins are measured by ultracentrifugal or electrophoretic methods

Page 25: lipids & dyslipoproteinemia

BLOOD SAMPLING & STORAGE PLASMA VS. SERUM Cont.- EDTA is the preferred anticoagulant - ♥- Heparin – X- Citrate – X STORAGE- When serum or plasma must be stored

for long periods it should be maintained at a temperature of -70⁰C.

- For short term storage, the samples can be kept at – 20⁰C.

Page 26: lipids & dyslipoproteinemia

LIPID & LIPOPROTEIN MEASUREMENT A. TAG measurementChemical Nonenzymatic MethodsGeneral Steps1. Extraction- To remove TAG from LP’s- Accomplished by using MeOH, EtOH,

isopropyl alcohol, Folch’s rgt & diethyl ether

- - removal of interferences by zeolite

Page 27: lipids & dyslipoproteinemia

A. TAG MEASUREMENT

2. Hydrolysis of TAG into FFA & Glycerol- By saponification w/ alcoholic KOH

3. Measurement of Glycerol- The glycerol liberated is oxidized by

periodate to HCHO & quantified by using any of the ff:

- Eegrine reaction- Schryver’s reaction- Pay’s reaction- Hantzsch reaction (method of choice)

Page 28: lipids & dyslipoproteinemia

A. TAG MEASUREMENT Enzymatic Methods- Based on the hydrolysis of TAG & the

measurement of glycerol that is released in the reaction:

LPS- TAG + 3H2O glycerol + fatty acid- Methods:- Boculo David - Megraw - Winartasaputra- Nagele - Trinder

Page 29: lipids & dyslipoproteinemia

B. CHOLESTEROL MEASUREMENT Chemical Nonenzymatic Methods4 General Steps1. Extraction- Using Bloor’s rgt (3:1 EtOH – ether) or

zeolite extraction2. Saponification- Using KOH3. Purification- Using digitonin4. Color development- May proceed w/ the Leibermann-

Burchardt reaction or Salkowski reaction

Page 30: lipids & dyslipoproteinemia

B. CHOLESTEROL MEASUREMENT

Leibermann - Burchardt reaction- Uses sulfuric acid & acetic anhydride to

produce an unstable green cholestadienyl monosulfonic acid; color stabilized by sodium sulfate

Zak or Salkowski reaction- Uses sulfuric acid & ferric ions to

produce a stable red to red – violet cholestadienyl disulfonic acid

Page 31: lipids & dyslipoproteinemia

CHOLESTEROL MEASUREMENT NONENZYMATIC 1 Step Methods- Zlatkis – Zak Boyle method- Ferro – Ham method- Pearson – Stern – MacGavack- Wybenga et al 2 Step Methods- Carr – Drekter 3 Step Methods- Abell – Kendall method (Standard reference

method) 4 Step Methods- Schoenheimer – Sperry - Parek – Jung- Sperry - webb

Page 32: lipids & dyslipoproteinemia

CHOLESTEROL MEASUREMENT: ENZYMATIC (CHOD – PAP) cholesterol ester

Cholesterol ester + H2O cholesterol + FFA

hydrolase

cholesterol

Cholesterol + O2 cholest – 4 – en – 3 – one + H2O2

oxidase

peroxidase

H2O2 + phenol + 4 aminoantipyrine quinoneimine dye

+ 2 H2O

Page 33: lipids & dyslipoproteinemia

LIPOPROTEIN MEASUREMENT 1. HDL Measurement- Polyanion precipitation- Electrophoresis – spectrophotometric

det’n- Ultracentrifugation ( reference method) 2. Chylomicrons / CM- Standing Plasma Test 3. Lipid Profile- Use of the Friedewald equation

Page 34: lipids & dyslipoproteinemia
Page 35: lipids & dyslipoproteinemia

THE NCEP GUIDELINES Testing & TreatmentCholesterol Goals:ATP III recommends a complete

lipoprotein profile as the initial test for evaluating blood cholesterol.

Testing should be performed on all adults aged 20 & older & should be repeated once every 5 years.

The need for a therapeutic lifestyle change & drug therapy

Page 36: lipids & dyslipoproteinemia

ATP III CLASIFICATION FOR LIPID VALUES

For Cholesterol: conversion factor to convert mg/dL to mM is 0.02586For triglyceride : conversion factor to convert mg / dL to mM is 0.011 LDL

CholesterolHDL

Cholesterol

Total Cholesterol

Triglyceride

<100 optimal < 40

low < 200

desirable < 150

normal

100-129

Near optimal / above optimal

≥ 90 high 200-239

Borderline

high

150 -199

Borderline high

130-159

Borderline

high

≥ 240 high 200 -499

high

160 -189

High ≥ 500 Very high

≥190 Very high

Page 37: lipids & dyslipoproteinemia

HYPERLIPIDEMIA DRUGS

Drug Class Mechanism of Action Example

Statins Lowers LDL cholesterol Lovastatin , simvastatin,Pravastatin, fluvastatin

Fibric acid derivatives

Lowers TAG Gemfibrosil, Fenofibrate

Bile acid resins

Lowers LDL cholesterol Colestipol, cholestyramine

Niacin (nicotinic acid)

Lowers TAG niacin

Page 38: lipids & dyslipoproteinemia

E. LIPIDS, LIPOPROTEINS & DISEASE

CHD (coronary heart

disease) Atherosclerosis

Page 39: lipids & dyslipoproteinemia

RISK FACTORS OF CHDPositive

Age: Male 45 yrs and above, Females 55 yrs and above or premature menopause without estrogen therapyFamily history of premature CHDCurrent cigarette smokingHypertension (equal or more than 140/90 mmHg or on antihypertensive therapy)Low HDL-Chol (<35 mg/dl)Diabetes mellitus

NegativeHigh HDL-Cholesterol (equal to or above 60 mg/dl)

Page 40: lipids & dyslipoproteinemia

HIGH CHOLESTEROL WITH HIGH LDL - CHOLESTEROL

hyperbetalipoproteine-

mia Elevated LDL – C Normal TAG High cardiac risk Commonly

encountered

SPECIFIC DISEASES- Polygenic (Nonfamilial)

Hypercholesterolemia- Familial

hypercholesterolemia/FH

- Familial Defective Apo B

- Sitosterolemia

Page 41: lipids & dyslipoproteinemia

HIGH TAG WITH NORMAL CHOLESTEROL

Due to the elevation of TAG rich particles

Hyperprebetalipo – proteinemia

secondary to excess alcohol & high carbohydrate intake

SPECIFIC DISEASES- Diabetic dyslipidemia- Familial

hypertriglyceridemia- Lipoprotein lipase

deficiency- Apo C II deficiency- Apo C III excess

Page 42: lipids & dyslipoproteinemia

LIPIDOSES

A group of inherited disorders characterized by the accumulation of lipids in tissues especially the “brain” due to a deficiency in a particular sphingolipid catabolic enzyme

Page 43: lipids & dyslipoproteinemia

LIPIDOSES: Niemann – Pick disease- Deficiency in sphingomyelinase & accumulation of

sphingomyelin Gaucher’s disease- Deficiency in β – D glucosidase & the

accumulation of glucocerebroside Krabbe’s disease- Deficiency in β – D galactosidase & the

accumulation of galactocerebrosides Fabry’s disease- Deficiency in α – D galactosidase & the

accumulation of ceramide trihexoside Tay – Sach’s disease- Deficiency in β – D hexaminidase & the

accumulation of β - sulfogalactocerebroside

Page 44: lipids & dyslipoproteinemia

KEY POINT SUMMARY Ultracentrifugation & electrophoretic techniques

are of historical significance, MOST useful lipid & lipoprotein testing are now enzymatic.

LDL – cholesterol can be measured directly , but is usually calculated using the Friedewald formula.

LDL – C is now considered the MOST important value in assessing cardiac risk & directing therapy.

The profile for initial adult screening aged 20 & above, includes TC, TAG, HDL – C & LDL – C & should be repeated every 5 years.

Page 45: lipids & dyslipoproteinemia

F. REFERENCES INTERNET SOURCES Bhagavan NV (2002).

Medical Biochemistry. San Diego: Harcourt/Academic Press. ISBN 0-12-095440-0. http://books.google.com/?id=vT9YttFTPi0C&printsec=frontcover. 

http://biology.clc.uc.edu/courses/bio104/lipids.htm

BOOK SOURCES Clinical Diagnosis and

Management by Laboratory Methods / John Bernard Henry.

20th ed. 224 – 248

Henry’s Clinical Diagnosis and Management by Laboratory

Methods / Richard McPherson & Mathhew Pincus. 21st ed. 200 –

219 Clinical Chemistry: Principles,

Procedures & Correlations / Michael Bishop, Janet Engelkirk

& Edward Fody. 4th ed. 232 – 259 Southwestern University

College of Medical Technology Clinical Internship Manual / 2005

ed. Southwestern University College of

Medical Technology: Lecture Handbook in Routine Clinical

Chemistry/ Julius Mario. 2008 ed. 44 -54

Danny Donor ♥

Page 46: lipids & dyslipoproteinemia

THANKS FORLISTENING…

learn to love

the things you

hate

You're on the road to success when you realize that failure is only a detour.